Copy link:

Sale
NOBIVAC® Feline 1-HCPCh
NOBIVAC® Feline 1-HCPCh
NOBIVAC® Feline 1-HCPCh

Merck

NOBIVAC® Feline 1-HCPCh

No reviews yet Write a Review
SKU:
NOBFELHCPCH
UPC:
662858207316
Manufacturer:
Merck
Brand:
Nobivac
Was:  $175.99
Now: $145.99
Hurry up! only left
Adding to cart… The item has been added

Copy link:

  • Description Description
    Nobivac Feline 1-HCPCh (Eclipse 4) is recommended for the vaccination of healthy cats against diseases caused by feline Rhinotracheitis (feline Herpes), Calici, Panleukopenia, and Chlamydia Psittaci. Has been shown to block the replication of canine Parvovirus in cats. This vaccine goes beyond the core antigen protection to help prevent feline Chlamydophila infection. Optimal for healthy outdoor cats or cats that board frequently. Non-adjuvanted formula. Modified live viruses and bacteria. Recommended for use in healthy cats nine weeks of age or older.

  • Nobivac Feline 1-HCPCh (Eclipse 4) prevents Feline Rhinotracheitis, Calici, and Panleukopenia Modified live virus
  • Chlamydia Psittaci Modified live bacteria
  • Injectable vaccination
  • For healthy cats nine weeks of age or older
  • Optimal for healthy outdoor cats or cats that board frequently
  • Made in the USA

Nobivac is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.

  • Useful Info Useful Info

    Useful Info

  • Vaccinate healthy cats 9 weeks of age or older.
  • Transfer contents of the diluent vial to the Nobivac Feline 1-HCPCh vial aseptically.
  • Mix gently until dissolved. Use entire contents immediately after rehydration.
  • Two doses are required for primary immunization.
  • Initial vaccination: Inject 1 dose (1 ml) subcutaneously or intramuscularly at 9 weeks of age or older
  • Second vaccination: Inject 1 dose (1 ml) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.
  • Annual revaccination with one dose is recommended.

    • Warnings:
  • Contains gentamicin as a preservative
  • Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.
  • Do not vaccinate pregnant cats
  • The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.
    • Nobivac Feline 1-HCPCh (Eclipse 4) is recommended for the vaccination of healthy cats against diseases caused by feline Rhinotracheitis (feline Herpes), Calici, Panleukopenia, and Chlamydia Psittaci. Has been shown to block the replication of canine Parvovirus in cats. This vaccine goes beyond the core antigen protection to help prevent feline Chlamydophila infection. Optimal for healthy outdoor cats or cats that board frequently. Non-adjuvanted formula. Modified live viruses and bacteria. Recommended for use in healthy cats nine weeks of age or older.

  • Nobivac Feline 1-HCPCh (Eclipse 4) prevents Feline Rhinotracheitis, Calici, and Panleukopenia Modified live virus
  • Chlamydia Psittaci Modified live bacteria
  • Injectable vaccination
  • For healthy cats nine weeks of age or older
  • Optimal for healthy outdoor cats or cats that board frequently
  • Made in the USA

    • Nobivac is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.

    Useful Info

  • Vaccinate healthy cats 9 weeks of age or older.
  • Transfer contents of the diluent vial to the Nobivac Feline 1-HCPCh vial aseptically.
  • Mix gently until dissolved. Use entire contents immediately after rehydration.
  • Two doses are required for primary immunization.
  • Initial vaccination: Inject 1 dose (1 ml) subcutaneously or intramuscularly at 9 weeks of age or older
  • Second vaccination: Inject 1 dose (1 ml) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.
  • Annual revaccination with one dose is recommended.

    • Warnings:
  • Contains gentamicin as a preservative
  • Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.
  • Do not vaccinate pregnant cats
  • The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

    • Reviews